USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma
- The Francis Crick Institute, United Kingdom
- University of Oxford, United Kingdom
- CRUK Therapeutic Discovery Laboratories, United Kingdom
- Forma Therapeutics, United States
- Novartis Institutes of BioMedical Research, United States
- FORMA Therapeutics, United States
- University College London, United Kingdom
- Francis Crick Institute, United Kingdom
- Max Planck Institut, Dortmund, Germany
- Walter and Eliza Hall Institute of Medical Research, Australia
- Liverpool University, United Kingdom
Peer review process
This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.
History
- Version of Record published
- Accepted Manuscript published
- Accepted
- Received
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma
eLife 10:e71596.
https://doi.org/10.7554/eLife.71596
